secwatch.observer — SEC 8-K summary
======================================

Issuer:     OCULAR THERAPEUTIX, INC (OCUL)
CIK:        0001393434
Form:       8-K
Filed at:   2024-03-11T23:59:59+00:00
Accession:  0001104659-24-032974
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocular Therapeutix Q4 net loss $29.2M, revenue $14.8M; cash $195.8M plus $325M PIPE
--------------------------------------------------------------------------------

- Q4 net loss $29.2M ($0.35 loss per share); revenue $14.8M, up 5% YoY.
- Full year 2023 net loss $80.7M ($1.01 loss per share); revenue $58.4M, up 13.4%.
- Cash $195.8M at year-end; Feb 2024 PIPE added $325M gross proceeds, funding into at least 2028.
- Appointed Pravin Dugel as Executive Chairman and three key retinal care leaders.
- Phase 3 AXPAXLI SOL-1 screening underway; topline data for diabetic retinopathy and PAXTRAVA glaucoma expected Q2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1393434/000110465924032974/0001104659-24-032974-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1393434/000110465924032974/tm248311d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-032974

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer